HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX)

Key Points

• HC Wainwright expects InflaRx to report a Q3 2026 loss of $0.09 per share and maintains a “Buy” rating with an $8.00 price target. Its estimates project continued losses through 2028.
• InflaRx’s latest quarterly results missed expectations, with an EPS loss of $0.11 versus the consensus loss estimate of $0.07.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $7.33, while institutional investors own 42.39% of the company.

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of InflaRx in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for InflaRx's current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for InflaRx's Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.38) EPS.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald lifted their price target on shares of InflaRx from $4.00 to $6.00 and gave the stock an "overweight" rating in a research note on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Wednesday, June 24th. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an "outperform" rating and a $5.00 target price for the company. Wall Street Zen upgraded InflaRx from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Finally, Guggenheim reissued a "buy" rating and set a $14.00 price target on shares of InflaRx in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, InflaRx presently has a consensus rating of "Moderate Buy" and an average target price of $7.33.

InflaRx Price Performance

IFRX stock opened at $1.84 on Monday. InflaRx has a twelve month low of $0.78 and a twelve month high of $2.95. The stock has a market capitalization of $133.01 million, a price-to-earnings ratio of -3.17 and a beta of 2.48. The firm's fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $1.53.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04).

Hedge Funds Weigh In On InflaRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its holdings in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares in the last quarter. HRT Financial LP bought a new position in InflaRx during the 4th quarter worth about $47,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company's stock valued at $53,000 after purchasing an additional 19,200 shares during the period. Insigneo Advisory Services LLC purchased a new position in InflaRx during the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd bought a new stake in shares of InflaRx in the 4th quarter valued at about $104,000. Institutional investors own 42.39% of the company's stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source